Orthofix Medical/$OFIX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Orthofix Medical
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
- Ticker
- $OFIX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,605
- Headquarters
- Lewisville, United States
- Website
- orthofix.com
Orthofix Medical Metrics
BasicAdvanced
$363M
-
-$1.53
0.67
-
Price and volume
Market cap
$363M
Beta
0.67
52-week high
$16.42
52-week low
$8.50
Average daily volume
474K
Financial strength
Current ratio
2.841
Quick ratio
1.526
Long term debt to equity
0.603
Total debt to equity
0.61
Interest coverage (TTM)
-1.81%
Profitability
EBITDA (TTM)
20.928
Gross margin (TTM)
71.26%
Net profit margin (TTM)
-7.41%
Operating margin (TTM)
-4.51%
Effective tax rate (TTM)
-2.39%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-2.75%
Return on equity (TTM)
-13.91%
Valuation
Price to revenue (TTM)
0.431
Price to book
0.85
Price to tangible book (TTM)
2.16
Price to free cash flow (TTM)
-12.914
Free cash flow yield (TTM)
-7.74%
Free cash flow per share (TTM)
-0.691
Growth
Revenue change (TTM)
2.99%
Earnings per share change (TTM)
-51.82%
3-year revenue growth (CAGR)
11.66%
10-year revenue growth (CAGR)
7.39%
3-year earnings per share growth (CAGR)
-28.49%
10-year earnings per share growth (CAGR)
33.31%
What the Analysts think about Orthofix Medical
Analyst ratings (Buy, Hold, Sell) for Orthofix Medical stock.
Analyst projections of the future price of Orthofix Medical stock.
Bulls say / Bears say
Orthofix raised its 2026 sales outlook to $845–855 million and adjusted EBITDA outlook to $95–98 million. The midpoint implies about 80 basis points of adjusted EBITDA margin expansion against 2025. (Orthofix Medical Inc.)
Core growth platforms showed encouraging demand: Global Limb Reconstruction grew 11% on a constant-currency basis and Spine Fixation grew 10%. This gives the company growth drivers beyond its more mature therapeutic products. (Orthofix Medical Inc.)
CMS restored Medicare reimbursement for bone growth stimulators to its previous level, removing a recent headwind for Therapeutic Solutions. The business still grew 3% year on year in Q2 despite the temporary reimbursement pressure, which supports the prospect of a stronger second half. (Orthofix Medical Inc.)
The company remains loss-making and cash-hungry: it reported a $15.8 million Q2 net loss and used $23.8 million of operating cash in the first half, while free cash flow was negative $47.1 million. This leaves execution and funding dependent on a sustained improvement in cash generation. (SEC)
Smaller US spine distributors remain weaker than management expects, and the company forecast Q3 sales broadly flat against Q2. A roughly $15 million European inventory arrangement supports 2026 sales but is expected to be followed by a $22 million sales headwind in 2027. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Orthofix Medical Financial Performance
Revenues and expenses
Orthofix Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
Orthofix Medical News
AllArticlesVideos
Funds containing Orthofix Medical
Fund name | Fund size | $OFIX weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.03% |
iShares Ageing Population£AGES | $953M | 0.03% |
iShares Ageing Population€AGED | $903M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.